138 related articles for article (PubMed ID: 11411896)
1. Naproxen particle design using porous starch.
Nagata K; Okamoto H; Danjo K
Drug Dev Ind Pharm; 2001 Apr; 27(4):287-96. PubMed ID: 11411896
[TBL] [Abstract][Full Text] [Related]
2. Effects of particle morphology, pore size and surface coating of mesoporous silica on Naproxen dissolution rate enhancement.
Guo Z; Liu XM; Ma L; Li J; Zhang H; Gao YP; Yuan Y
Colloids Surf B Biointerfaces; 2013 Jan; 101():228-35. PubMed ID: 23010024
[TBL] [Abstract][Full Text] [Related]
3. Changes in the solid state of anhydrous and hydrated forms of sodium naproxen under different grinding and environmental conditions: Evidence of the formation of new hydrated forms.
Censi R; Rascioni R; Di Martino P
Eur J Pharm Biopharm; 2015 May; 92():192-203. PubMed ID: 25796350
[TBL] [Abstract][Full Text] [Related]
4. Characterization of physicochemical properties of naproxen systems with amorphous beta-cyclodextrin-epichlorohydrin polymers.
Mura P; Faucci MT; Maestrelli F; Furlanetto S; Pinzauti S
J Pharm Biomed Anal; 2002 Aug; 29(6):1015-24. PubMed ID: 12110386
[TBL] [Abstract][Full Text] [Related]
5. Development of a solid self-microemulsifying drug delivery system (SMEDDS) for solubility enhancement of naproxen.
Čerpnjak K; Zvonar A; Vrečer F; Gašperlin M
Drug Dev Ind Pharm; 2015; 41(9):1548-57. PubMed ID: 25308746
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine.
Kasten G; Lobo L; Dengale S; Grohganz H; Rades T; Löbmann K
Eur J Pharm Biopharm; 2018 Nov; 132():192-199. PubMed ID: 30266670
[TBL] [Abstract][Full Text] [Related]
7. Interaction of naproxen with noncrystalline acetyl beta- and acetyl gamma-cyclodextrins in the solid and liquid state.
Bettinetti G; Mura P; Faucci MT; Sorrenti M; Setti M
Eur J Pharm Sci; 2002 Feb; 15(1):21-9. PubMed ID: 11803128
[TBL] [Abstract][Full Text] [Related]
8. Thermal behavior and dissolution properties of naproxen from binary and ternary solid dispersions.
Mura P; Faucci MT; Manderioli A; Bramanti G; Parrini P
Drug Dev Ind Pharm; 1999 Mar; 25(3):257-64. PubMed ID: 10071817
[TBL] [Abstract][Full Text] [Related]
9. Development and characterization of naproxen-chitosan solid systems with improved drug dissolution properties.
Mura P; Zerrouk N; Mennini N; Maestrelli F; Chemtob C
Eur J Pharm Sci; 2003 May; 19(1):67-75. PubMed ID: 12729863
[TBL] [Abstract][Full Text] [Related]
10. Interaction of naproxen with alpha-cyclodextrin and its noncyclic analog maltohexaose.
Bettinetti G; Sorrenti M; Negri A; Setti M; Mura P; Melani F
Pharm Res; 1999 May; 16(5):689-94. PubMed ID: 10350012
[TBL] [Abstract][Full Text] [Related]
11. Spray drying of naproxen and naproxen sodium for improved tableting and dissolution - physicochemical characterization and compression performance.
Al-Zoubi N; Odeh F; Partheniadis I; Gharaibeh S; Nikolakakis I
Pharm Dev Technol; 2021 Feb; 26(2):193-208. PubMed ID: 33211618
[TBL] [Abstract][Full Text] [Related]
12. [Study on porous starch as solid dispersion carrier of total Epimedium flavonoids].
Yan HM; Jia XB; Zhang ZH; Sun E; Xu YH
Zhongguo Zhong Yao Za Zhi; 2015 May; 40(9):1723-6. PubMed ID: 26323136
[TBL] [Abstract][Full Text] [Related]
13. Effect of PEG 4000 on the dissolution rate of naproxen.
Vélaz I; Sánchez M; Martín C; Martínez-Ohárriz MC
Eur J Drug Metab Pharmacokinet; 1998; 23(2):103-8. PubMed ID: 9725465
[TBL] [Abstract][Full Text] [Related]
14. Particle design of naproxen-disintegrant agglomerates for direct compression by a crystallo-co-agglomeration technique.
Maghsoodi M; Taghizadeh O; Martin GP; Nokhodchi A
Int J Pharm; 2008 Mar; 351(1-2):45-54. PubMed ID: 17980983
[TBL] [Abstract][Full Text] [Related]
15. Naproxen Microparticulate Systems Prepared Using In Situ Crystallisation and Freeze-Drying Techniques.
Solaiman A; Tatari AK; Elkordy AA
AAPS PharmSciTech; 2017 Jul; 18(5):1438-1446. PubMed ID: 28004343
[TBL] [Abstract][Full Text] [Related]
16. How Molecular Mobility, Physical State, and Drug Distribution Influence the Naproxen Release Profile from Different Mesoporous Silica Matrices.
d'Orey P; Cordeiro T; Lourenço MAO; Matos I; Danède F; Sotomayor JC; Fonseca IM; Ferreira P; Correia NT; Dionísio M
Mol Pharm; 2021 Mar; 18(3):898-914. PubMed ID: 33461296
[TBL] [Abstract][Full Text] [Related]
17. Crystal forms of naproxen.
Song JS; Sohn YT
Arch Pharm Res; 2011 Jan; 34(1):87-90. PubMed ID: 21468919
[TBL] [Abstract][Full Text] [Related]
18. Studying of crystal growth and overall crystallization of naproxen from binary mixtures.
Kaminska E; Madejczyk O; Tarnacka M; Jurkiewicz K; Kaminski K; Paluch M
Eur J Pharm Biopharm; 2017 Apr; 113():75-87. PubMed ID: 28034808
[TBL] [Abstract][Full Text] [Related]
19. Effects of liquisolid formulations on dissolution of naproxen.
Tiong N; Elkordy AA
Eur J Pharm Biopharm; 2009 Nov; 73(3):373-84. PubMed ID: 19679184
[TBL] [Abstract][Full Text] [Related]
20. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen.
Löbmann K; Laitinen R; Grohganz H; Gordon KC; Strachan C; Rades T
Mol Pharm; 2011 Oct; 8(5):1919-28. PubMed ID: 21815614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
